The AMD ANNALS: A continuous initiative for the improvement of type 2 diabetes care
An erratum to this article was published (Diabetes Res Clin Pract, Apr 2024 ↗)
Authors' conclusion
The 2022 AMD Annals data show an improvement in the use of innovative drugs and in the overall quality of T2D care in everyday clinical practice. However, additional efforts are needed to reach the recommended targets for HbA1c and major CVD risk factors.
Study context
- Population
- Patients with T2D attending 295 diabetes centers in Italy (∼1/3 of Italian diabetes centers), 2022
- Participants
- 502,747 patients295 centers
- Outcome
- Quality-of-care indicators in T2D, 2022
Methodological detailsmulticentre, quality-of-care registry (AMD Annals Initiative), electronic clinical records
- Multicentre
- Quality-of-care registry (AMD Annals Initiative)
- Electronic clinical records
Main finding
As reported in the abstract
- HbA1c ≤7.0%
- 54.6%
- Blood pressure <130/80 mmHg
- 23.0%
- LDL-C <70 mg/dl
- 34.3%
- At target for all risk factors
- 5.2%
- On SGLT2i
- 29.0%
- On GLP-1 RA
- 27.5%
- Q-score <15
- 3.2%
Observational data: associations, not effects.
Further findings
Use of GLP-1 RA or SGLT2i in established cardiovascular disease (CVD)
- Treated with GLP-1 RA or SGLT2i, established CVD
- 59.7%
SGLT2i use in impaired renal function and HF
- SGLT2i, impaired renal function
- 26.6%
- SGLT2i, HF
- 49.3%
Original publication
The AMD ANNALS: A continuous initiative for the improvement of type 2 diabetes care. Diabetes Res Clin Pract. Published 19 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →